Lv71
4900 积分 2021-11-18 加入
First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need
5天前
已关闭
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
7天前
已完结
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
24天前
已完结
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
24天前
已完结
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
25天前
已完结
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
25天前
已完结
Advances in RAS Therapeutics for Pancreatic Cancer
25天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
25天前
已完结
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
29天前
已完结
Next-generation KRAS-G12C inhibitor D3S-001 shows promise
1个月前
已完结
皖公网安备34019202002308
